# K203592: Tigertriever and Tigertriever 17 Revascularization Devce

- Pathway: 510(k) (Traditional)
- Applicant: Rapid Medical, Ltd.
- Decided: Mar 23, 2021 after 105 days
- Product code: NRY (Catheter, Thrombus Retriever)
- Device class: 2
- Regulation: 21 CFR 870.1250
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 8 generations back to K003410 (2001). 14 ancestors in all.
5 later devices descend from it; 4 cite it directly.
0 of 20 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K141491: Solitaire 2 Revascularization Device, Micro Therapeutics, Inc. d/b/a ev3 Neurovascular (2014) Summary page 4.

## Most influential descendants
- K220808: Tigertriever 13 Revascularization Device (2022), 2 descendants of its own
- K260617: Tigertriever 13 Ultra Revascularization Device (2026), 0 descendants of its own
- K253062: Tigertriever 25 Revascularization Device (2026), 0 descendants of its own
- K251603: Tigertriever 17 Ultra Revascularization Device (2025), 0 descendants of its own
- K230429: Tigertriever 21 Revascularization Device, Tigertriever 17 Revascularization Device, Tigertriever 13 Revascularization Device (2023), 0 descendants of its own

## Indications for use
The Tigertriever Revascularization Device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA), or who fail IV t-PA therapy, are candidates for treatment.

Source page: https://510kreport.com/device/K203592
Methodology: https://510kreport.com/methodology